Fewer injections. More moments that matter.
THE PROBLEM
This is central vision loss
Age-related Macular Degeneration (AMD) is the leading cause of blindness. Effective drugs exist, but the eye clears them within days. Patients need injections every month. Many fall behind, and missed doses can mean permanent vision loss.
0M
AMD patients in the world
0.0M
AMD patients in the world
0
injections every year, often for life
Our approach
A longer-lasting treatment
Small by design
A biodegradable implant, about the size of a grain of rice, is designed to carry anti-VEGF proteins.
WHY BINA
Feedback-driven solution
More than 100 interviews with industry, clinical and regulatory experts shaped our design.
| Feature | Current | Bina |
|---|---|---|
| Durability | Monthly | 4+ months |
| Drug | Approved protein drugs | The same protein drugs, longer acting |
| Removal | — | Biodegradable |
| Dose control | Fixed | Optional light-triggered boost |
Team
Rooted at Queen's University
Fateme Rezagholizade
PhD Candidate, Biomed. Eng. at Queen's University
Co-Founder / Technical Lead
Brian Amsden
Professor at Queen's University
Principal Investigator / Scientific Advisor
Stage & milestones
Early stage, moving carefully.
Done
Lab proof of concept
Our formulation released a model protein with its activity intact.
Done
Market discovery
More than 100 interviews with industry, clinical and regulatory experts.
In progress
Preclinical studies
Animal safety results expected spring 2027.
Next
Company incorporation and IP terms
IP terms with Queen's and a patent application by early summer 2027.
Next
NSERC Idea to Innovation application
To be submitted by the end of summer 2027.
Later
Clinical studies
First-in-human studies after preclinical go/no-go gates.
Later
Pharma partnerships
Feasibility studies with drug originators and biosimilar makers.
Contact
Investors, clinicians and pharma partners.
Tell us a little about yourself and we'll be in touch.